HER2 heterogeneity affects trastuzumab responses and survival in patients with HER2-positive metastatic breast cancer.
about
Prognostic significance of c-Met in breast cancer: a meta-analysis of 6010 casesPoor efficacy response to trastuzumab therapy in advanced gastric cancer with homogeneous HER2 positive and non-intestinal type.Conditional internalization of PEGylated nanomedicines by PEG engagers for triple negative breast cancer therapyPrognostic and predictive values of EGFR overexpression and EGFR copy number alteration in HER2-positive breast cancer.Analysis of in vitro ADCC and clinical response to trastuzumab: possible relevance of FcγRIIIA/FcγRIIA gene polymorphisms and HER-2 expression levels on breast cancer cell lines.Hormone receptor status predicts the clinical outcome of human epidermal growth factor 2-positive metastatic breast cancer patients receiving trastuzumab therapy: a multicenter retrospective studyAddressing challenges of heterogeneous tumor treatment through bispecific protein-mediated pretargeted drug delivery.Expression levels of HER2 and MRP1 are not prognostic factors of long-term survival in 829 patients with esophageal squamous cell carcinomaExpression of breast cancer stem cell markers as predictors of prognosis and response to trastuzumab in HER2-positive breast cancerHER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patientsThe assessment of HER2 status in breast cancer: the past, the present, and the future.'Non-classical' HER2 FISH results in breast cancer: a multi-institutional study.HER2 gene copy number and breast cancer-specific survival.Breast carcinomas with low amplified/equivocal HER2 by Ish: potential supporting role of multiplex ligation-dependent probe amplification.Mek activity is required for ErbB2 expression in breast cancer cells detached from the extracellular matrix.Diversity index as a novel prognostic factor in breast cancer.HER2 intratumoral heterogeneity is independently associated with incomplete response to anti-HER2 neoadjuvant chemotherapy in HER2-positive breast carcinoma.Efficacy of Pemetrexed-based Chemotherapy in Comparison to Non-Pemetrexed-based Chemotherapy in Advanced, ALK+ Non-Small Cell Lung Cancer.Moderate level of HER2 expression and its prognostic significance in breast cancer with intermediate grade.Prognostic implications of HER2 heterogeneity in gastric cancer.Oncogenic transformation of normal breast epithelial cells co-cultured with cancer cellsA small molecule targeting myoferlin exerts promising anti-tumor effects on breast cancerRelationship between gene status and selected potential biological features related to trastuzumab resistance and its influence on survival of breast cancer patients undergoing trastuzumab adjuvant treatmentIntratumor heterogeneity defines treatment-resistant HER2+ breast tumors
P2860
Q28087523-37AACD93-3CDC-4D0A-ABF0-343A7ED1C381Q33779412-8FCC4A4A-F98E-40A7-8F12-D3CB7030D759Q33802940-329636D4-F03D-4859-9685-DF5AEB8CDA6DQ35677713-1FD1CF53-FB07-4379-B695-596F3A30C019Q36139709-33E96891-4522-417B-B548-2EFBD072B57CQ36288976-0C7786A6-2B3C-4BC4-8555-5B2AAB9BFA6CQ36395999-A556C51B-0560-4A2D-8C19-2964B87FC82AQ36503276-6BD91226-A373-43FB-A6CC-C9D04D8757E2Q36898399-2CC15571-491B-4027-BFFF-EAD03739D998Q37075632-70D2E0C0-DDB3-4A65-93ED-BBD4A0A3D470Q38802932-7CD3FE5E-A3CC-42B9-BF61-25274C455ECEQ39292642-D9C8DE68-6CDD-4E11-852D-36B153E3941FQ40714642-8DB8EB9C-F6B1-4A58-A2FE-CB86A8BF5F7FQ42377436-86045D55-BD01-40D2-A8AC-F0A2762A7258Q47102400-83ACE7FE-FECD-4B83-BBDD-9C791D686A65Q47162348-7066A035-3D11-4840-AB8A-DDE7E6AEE8B2Q47965547-B843D7DD-710B-4597-AFB4-E75083533521Q50045235-AE1B2CBD-E18D-4E8A-BA0D-0A263C0AD500Q53523972-C8817EC6-1624-4DE8-9F66-C7C9C42CCC58Q55261916-4BF56B26-CAA0-4EB4-BD49-31DDDC69BD9FQ58721230-550BE264-38A6-496E-BC6C-06C50E104B58Q58743761-4146F662-590C-4FB1-95B2-7C38D6CC9A89Q58801931-433937EC-4613-40A7-8229-398D4E35C3BBQ59132342-DEA8DC4C-FADB-441E-B46D-0E5EC126B68F
P2860
HER2 heterogeneity affects trastuzumab responses and survival in patients with HER2-positive metastatic breast cancer.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
HER2 heterogeneity affects tra ...... tive metastatic breast cancer.
@en
HER2 heterogeneity affects tra ...... tive metastatic breast cancer.
@nl
type
label
HER2 heterogeneity affects tra ...... tive metastatic breast cancer.
@en
HER2 heterogeneity affects tra ...... tive metastatic breast cancer.
@nl
prefLabel
HER2 heterogeneity affects tra ...... tive metastatic breast cancer.
@en
HER2 heterogeneity affects tra ...... tive metastatic breast cancer.
@nl
P2093
P356
P1476
HER2 heterogeneity affects tra ...... tive metastatic breast cancer.
@en
P2093
Eun Joo Kim
Gyungyub Gong
Han Suk Ryu
Hee Jin Lee
In Ae Park
Jee Hyun Kim
Koung Jin Suh
Kyung Hae Jung
Min Hye Jang
P304
P356
10.1309/AJCPIRL4GUVGK3YX
P407
P577
2014-12-01T00:00:00Z